Orchestra BioMed receives $20 million from Medtronic under financing pact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
May 6, 2026 8:00 AM EDTPayment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (BACKBEAT Trial) evaluating Atrioventricular Interval Modulation Therapy (AVIM Therapy) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and MedtronicThis payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq:... More
